新型低成本非阀门青光眼引流装置与Ahmed阀首年手术效果比较
该回顾性比较干预研究纳入83例患者共88眼,36眼接受Ahmed青光眼阀(AGV)、52眼接受新型非阀门Aurolab水引流植入物(AADI),比较难治性青光眼手术结局。AADI组总体成功率92.3%高于AGV组80.5%(p<0.001),末次随访眼压与抗青光眼药物数均显著低于AGV组,两组LogMAR最佳矫正视力均改善,并发症率相当(44.2% vs 52.7%,p=0.59)。
要点
- AADI组总体成功率92.3%高于AGV组80.5%(p<0.001)。
- 末次随访眼压中位数AADI 14 mmHg vs AGV 16 mmHg,AADI组显著更低(p<0.001)。
- 并发症率AADI 44.2% vs AGV 52.7%,两组相当(p=0.59)。
核心结论
- 两种手术均能有效降低眼压和减少抗青光眼药物需求,但AADI组总体成功率更高、末次随访眼压及所需抗青光眼药物数显著更低。
- 作者认为这一可负担的引流装置可能对中低收入国家难治性青光眼的管理产生巨大影响。
研究设计与样本
- 共纳入83例患者88眼,其中36眼接受AGV、52眼接受AADI;术前参数两组相似。
主要发现
- AADI中位随访13个月、AGV中位随访12个月。
- 总体成功率AADI 92.3% vs AGV 80.5%(p<0.001)。
- 末次随访眼压中位数(四分位数;IQR)AADI 14(10,15;5)mmHg vs AGV 16(14,20;6)mmHg,AADI组显著更低(p<0.001)。
- 末次随访抗青光眼药物数中位数(四分位数;IQR)AADI 0(0,1;1) vs AGV 2(1,2.75;1.75),AADI组显著更低(p<0.001)。
- 两组LogMAR最佳矫正视力均改善;并发症率AADI 44.2% vs AGV 52.7%,两组相当(p=0.59)。
关键数值与推荐
- 主要结局指标为眼压,次要结局指标为抗青光眼药物、LogMAR最佳矫正视力及并发症。
- AADI为低成本、本土制造、基于Baerveldt青光眼装置设计的非阀门引流装置;AGV为阀门装置。
临床怎么用
- 原文结论认为两种手术均能有效降低眼压并减少抗青光眼药物需求,AADI组总体成功率更高且眼压与所需药物数显著更低。
- 原文指出该可负担的引流装置可能对中低收入国家难治性青光眼的管理产生巨大影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A new low-cost, indigenously manufactured, non-valved glaucoma drainage device (GDD) has been introduced and its design is based on the Baerveldt Glaucoma Device. We aim to demonstrate the efficacy and safety of this GDD (Aurolab aqueous drainage implant, AADI) vis-à-vis the valved device, Ahmed glaucoma valve (AGV), in the management of refractory glaucomas. DESIGN: Retrospective, comparative, interventional. PARTICIPANTS: Case review of consecutive patients who underwent GDD surgery by a single fellowship-trained surgeon at a Tertiary Centre between January 2014 and November 2016. PRIMARY OUTCOME MEASURE: Intraocular pressure (IOP). SECONDARY: Antiglaucoma medication (AGM), LogMAR best-corrected visual acuity (BCVA), complications. RESULTS: A total of 88 eyes of 83 patients were included; 36 eyes received AGV and 52 AADI. Preoperative parameters were similar between groups. Median follow-up was 13 and 12 months for AADI and AGV, respectively. Overall success rate was higher in AADI (92.3%) vs AGV (80.5%) (p<0.001). The median IOP in mm Hg (Quartiles; IQR) (AADI 14 (10,15;5) vs AGV 16 (14,20;6)) and AGM (AADI: 0 (0,1;1) vs AGV 2 (1,2.75;1.75)) was significantly lower in the AADI group at last follow-up (p<0.001). LogMAR BCVA improved in both groups; complication rates (AADI 44.2% vs AGV 52.7%) were comparable (p=0.59). CONCLUSIONS: Both procedures were effective in reduction of IOP and need for AGM. Nevertheless, overall success rate was higher in the AADI group and IOP and number of AGM required was significantly lower in the AADI group; this affordable GDD could have a tremendous impact in the management of refractory glaucomas in low-income to middle-income countries.
引用
- Pathak Ray V, Rao DP. Surgical outcomes of a new affordable non-valved glaucoma drainage device and Ahmed glaucoma valve: comparison in the first year. Br J Ophthalmol. 2018. PMID: 29945893. doi:10.1136/bjophthalmol-2017-311716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。